Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia

Rahadi, Arie and Mahardya, Rizki Tsalatshita Khair and Listiani, Putri and Herlinawaty, Eva and Nugraha, Ryan Rachmad and Budiman, Dani Ramdhani and Suharlim, Christian (2025) Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia. International Journal of Technology Assessment in Health Care, 41 (1). ISSN 02664623

[thumbnail of 451.pdf] Text
451.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.

Download (558kB) | Request a copy

Abstract

Objectives Cost-effectiveness models fully informed by real-world epidemiological parameters yield the best results, but they are costly to obtain. Model calibration using real-world data/evidence (RWD/E) on routine health indicators can provide an alternative to improve the validity and acceptability of the results. We calibrated the transition probabilities of the reference chemotherapy treatment using RWE on patient overall survival (OS) to model the survival benefit of adjuvant trastuzumab in Indonesia. Methods A Markov model comprising four health states was initially parameterized using the reference-treatment transition probabilities, obtained from published international evidence. We then calibrated these probabilities, targeting a 2-year OS of 86.11 percent from the RWE sourced from hospital registries. We compared projected OS duration and life-years gained (LYG) before and after calibration for the Nelder-Mead, Bound Optimization BY Quadratic Approximation, and generalized reduced gradient (GRG) nonlinear optimization methods. Results The pre-calibrated transition probabilities overestimated the 2-year OS (92.25 percent). GRG nonlinear performed best and had the smallest difference with the RWD/E OS. After calibration, the projected OS duration was significantly lower than their pre-calibrated estimates across all optimization methods for both standard chemotherapy (¼7.50 vs. 11.00 years) and adjuvant trastuzumab (¼9.50 vs. 12.94 years). LYG measures were, however, similar (¼2 years) for the pre-calibrated and calibrated models. Conclusions RWD/E calibration resulted in realistically lower survival estimates. Despite the little difference in LYG, calibration is useful to adapt external evidence commonly used to derive transition probabilities to the policy context, thereby enhancing the validity and acceptability of the modeling results. © The Author(s), 2025. Published by Cambridge University Press.

Item Type: Article
Additional Information: Cited by: 0; All Open Access; Gold Open Access; Green Open Access
Uncontrolled Keywords: Antineoplastic Agents, Immunological; Breast Neoplasms; Calibration; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Indonesia; Markov Chains; Middle Aged; Probability; Survival Analysis; Trastuzumab; Diseases; Markov processes; Nonlinear programming; Risk assessment; trastuzumab; immunological antineoplastic agent; trastuzumab; Breast neoplasm; Cost effectiveness analysis; Early breast cancer; Generalized reduced gradient; Indonesia; Overall survival; Real-world; Survival; Transition probabilities; Trastuzumab; adjuvant therapy; adult; Article; calibration; cost effectiveness analysis; disease free survival; female; human; human epidermal growth factor receptor 2 positive breast cancer; Indonesian; loading drug dose; major clinical study; Markov chain; multiple cycle treatment; overall survival; adjuvant chemotherapy; breast tumor; cost benefit analysis; drug therapy; Indonesia; Markov chain; middle aged; mortality; probability; survival analysis; Chemotherapy
Subjects: R Medicine > RB Biomedical Sciences
Divisions: Faculty of Medicine, Public Health and Nursing > Biomedical Sciences
Depositing User: Yuliawati Dahniar Dahniar
Date Deposited: 14 Jul 2026 06:37
Last Modified: 14 Jul 2026 06:37
URI: https://ir.lib.ugm.ac.id/id/eprint/27936

Actions (login required)

View Item
View Item